Following Smart Money Baker Brothers LLC Investments In 2013 and Beyond Part 2 Print E-mail
By Scott Matusow   
Tuesday, 31 December 2013 11:14
In our first article covering The Baker Brothers LLC's investments, we listed a few stocks the investment firm holds significant positions in.
Read more...
 
5 Companies with Upcoming Catalysts that Should Rally into 2014 Print E-mail
By Scott Matusow   
Monday, 23 December 2013 04:21
In the developmental biopharma segment of the market that we follow daily at stockmatusow, stock prices sometimes experience volatile moves, especially as a near-term catalyst event approaches.
Read more...
 
Solta Medical Agrees To Be Acquired By Valeant, But Another Bid Might Emerge Print E-mail
By Scott Matusow   
Monday, 23 December 2013 04:18
On Monday, December 16th, Valeant (VRX) submitted what for the time being, is the winning bid to acquire Solta Medical Devices (SLTM).
Read more...
 
Kindred Bio –New, Hot Play on Animal Health Print E-mail
By Brian Wilson-Lead Contributor   
Monday, 23 December 2013 04:02
People really love their pets, and this is being reflected in the growth of animal health expenditure.  The following data is taken from the Animal Health Institute (AHI) (link).
Read more...
 
Changing the Landscape for Colorectal Cancer Screening Print E-mail
By Brian Wilson - Lead Contributor   
Thursday, 19 December 2013 10:39
Molecular diagnostics companies are continuing to show a lot of promise. Currently, we are taking a look at Exact Sciences (NASDAQ: EXAS) – one of the best up and coming plays in the colorectal cancer (CRC) space.
Read more...
 
The Baker Brothers LLC Investments In 2003 And Beyond Print E-mail
By Scott Matusow   
Thursday, 19 December 2013 10:01
Perhaps the most important buying indicator for a developmental pharma is who is buying the stock. At stockmatusow, we have had the most success with our trades and investments when we “follow the smart money.” When push comes to shove, we follow the smart money – period.
Read more...
 
NeoStem: Continued Progress and 2014 Catalysts Print E-mail
By Brian Wilson - Lead Contributor   
Wednesday, 18 December 2013 10:32
NeoStem (NASDAQ: NBS) recently announced the completion of the enrollment phase for their Phase II trial.
Read more...
 
Coronado: Autism Data May Be Interesting Print E-mail
By Brian Wilson-Lead Contributor   
Monday, 16 December 2013 08:55
Coronado Biosciences (NASDAQ: CNDO) is a company that is still picking up the pieces after the company’s most promising therapy – TSO (Trichuris suis ova, or CNDO-201) failed to meet its primary endpoint in the Phase II TRUST-I trial.
Read more...
 
ImmunoCellular: ICT-107 Fails Phase II Trial on Lack of Survival Benefit Print E-mail
By Staff and Wire Reports   
Thursday, 12 December 2013 11:04
ImmunoCellular (NYSE: IMUC) is currently trading about 60% lower on the day after the company announced that its glioblastoma drug candidate ICT-107 failed to meet its primary overall survival (OS) endpoint in Phase II trials.
Read more...
 
Clovis: Wrapping UP 2013 Print E-mail
By Brian Wilson - Lead Contributor   
Wednesday, 11 December 2013 12:26
A little over two months after Clovis Oncology (NASDAQ: CLVS) failed to find a bid after shopping itself to large pharmaceutical companies, we see that the company is continuing the development of its drug pipeline.
Read more...
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 16 of 56

Newsletter